Prostate cancer drug Xtandi has been given FDA approval for use as a first line treatment for metastatic castration-resistant prostate cancer (CRPC). The new approval allows Astellas and ...
Pfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend off growing competition in the market. The results of the phase 3 PROSPER trial show that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback